<DOC>
	<DOC>NCT02976766</DOC>
	<brief_summary>The purpose of this study is to determine whether gypenosides are neuroprotective in patients with acute optic neuritis.</brief_summary>
	<brief_title>Gypenosides Treatment for Optic Neuritis</brief_title>
	<detailed_description />
	<mesh_term>Optic Neuritis</mesh_term>
	<mesh_term>Neuritis</mesh_term>
	<criteria>Inclusion criteria 1. Male and female Chinese patients aged ≥18 to ≤60 years 2. Patients with a first episode of unilateral or bilateral optic neuritis 3. First symptoms of optic neuritis ≤28 days prior to the first administration of investigational product 4. Best corrected visual acuity in the worse eye ≤0.8 Exclusion criteria 1. Preexisting multiple sclerosis MS or NMO 2. Refractive media opacity 3. Hyperopia &gt;5 diopters, myopia &lt;5 diopters, or astigmatism &gt;3 diopters 4. Active tuberculosis, hepatitis, renal insufficiency, uncontrolled hypertension, diabetes mellitus, infection with HIV or syphilis, or any other conditions potentially interfering treatment trial 5. Other autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, etc) 6. Existing other retina or optic nerve diseases 7. Pregnant or females who plan to be pregnant during study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neuroprotection</keyword>
	<keyword>Clinical trial</keyword>
	<keyword>Traditional Chinese medicine</keyword>
	<keyword>Axonal loss</keyword>
	<keyword>Jiaogulan</keyword>
	<keyword>Gynostemma pentaphyllum</keyword>
	<keyword>Optical coherence tomography</keyword>
</DOC>